Skip to content

Clinical trials

Phase 1/2 Leukemia, Lymphocytic, Chronic, B-Cell trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Lymphocytic, Chronic, B-Cell Phase: Phase 1/2 Clear all

236 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20006
20016
20025
20038
20047
200514
20062
20079
200813
200911
20109
20119
201211
20138
201411
201510
201611
201713
20187
20198
202011
20216
20226
20236
20244
20255
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed117
Terminated44
Recruiting24
Unknown status19
Active, not recruiting18
Withdrawn12
Not yet recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center17
Fred Hutchinson Cancer Center14
National Cancer Institute (NCI)11
Mayo Clinic8
Gilead Sciences5
Dana-Farber Cancer Institute4
Genmab4
Masonic Cancer Center, University of Minnesota4
Pharmacyclics LLC.4
Acerta Pharma BV3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Lymphocytic, Chronic, B-Cell236
Lymphoma, Mantle-Cell90
Lymphoma, Follicular89
Lymphoma, Non-Hodgkin87
Lymphoma, Large B-Cell, Diffuse75
Lymphoma, B-Cell, Marginal Zone73
Leukemia64
Lymphoma61
Precursor Cell Lymphoblastic Leukemia-Lymphoma56
Hodgkin Disease42

Trials

Showing 51 to 75 of 236. Each trial links to its page on Pharma Observatory.

136 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.